TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07513181: Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

Sponsor: Athos Therapeutics Inc · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT07513181 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07513181 Rescue Dossier →